Poor glycemic control might compromise the efficacy of chemotherapy in non-small cell lung cancer patients with diabetes mellitus.

Xianghua ZengCheng XuJianan ChengChengdu SunZhongyu WangZhihua GongHaixia LongBo Zhu

Published in: Cancer medicine (2019)

Satisfactory glycemic control during platinum-based chemotherapy might provide a survival benefit to T2DM patients with NSCLC. Further studies are warranted to confirm our findings.

Keyphrases

glycemic control
type diabetes
blood glucose
locally advanced
weight loss
small cell lung cancer
insulin resistance
chemotherapy induced
blood pressure
skeletal muscle
metabolic syndrome
adipose tissue
tyrosine kinase